TCR V β 8.1-2 Antibody (3H2987): sc-73130

TCR V β 8.1-2 Antibody (3H2987) is a rat monoclonal IgG antibody that detects T cell receptor V β 8.1-2 (TCR V β 8.1-2) in mouse samples through immunoprecipitation (IP) and flow cytometry (FCM) applications. TCR V β 8.1-2 plays a crucial role in the immune response by recognizing specific foreign antigens, which is essential for the activation and proliferation of T cells. TCR V β 8.1-2 is part of the T cell receptor complex, primarily located on the surface of T cells, allowing recognition and response to pathogens effectively. TCR V β 8.1-2′s ability to bind to a diverse array of antigens is vital for the adaptive immune system, enabling T cells to distinguish between self and non-self entities, thus preventing autoimmune reactions while mounting an effective defense against infections. TCR V β 8.1-2 is particularly important in T cell development and differentiation, contributing to the generation of a diverse T cell repertoire through somatic recombination of gene segments. Genetic alterations in the TCR V β locus have been linked to various immunological disorders, highlighting TCR V β 8.1-2′s significance in maintaining immune homeostasis. TCR V β 8.1-2 Antibody (3H2987) serves as an invaluable tool for researchers studying T cell biology and immune responses in mouse models.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TCR V β 8.1-2 Antibody (3H2987) References:

1. T cell response in malaria pathogenesis: selective increase in T cells carrying the TCR V(beta)8 during experimental cerebral malaria.  |  Boubou, MI., et al. 1999. Int Immunol. 11: 1553-62. PMID: 10464176
2. Therapy against murine collagen-induced arthritis with T cell receptor V beta-specific antibodies.  |  Chiocchia, G., et al. 1991. Eur J Immunol. 21: 2899-905. PMID: 1836185
3. In vivo elimination of T cells expressing specific T-cell receptor V beta chains in mice susceptible to collagen-induced arthritis.  |  Goldschmidt, TJ., et al. 1990. Immunology. 69: 508-14. PMID: 2139866
4. Short-term administration of selected anti-T-cell receptor V beta chain specific MoAb reduces sialadenitis in MRL/lpr mice.  |  Skarstein, K., et al. 1995. Scand J Immunol. 42: 529-34. PMID: 7481557
5. In vivo preferential usage of TCR V beta 8 in Torpedo acetylcholine receptor immune response in the murine experimental model of myasthenia gravis.  |  Aimé-Sempé, C., et al. 1995. J Neuroimmunol. 58: 191-200. PMID: 7759608
6. Attenuation of lpr-graft-versus-host disease (GVHD) in MRL/lpr spleen cell-injected SCID mice by in vivo treatment with anti-V beta 8.1,2 monoclonal antibody.  |  Hosaka, N., et al. 1994. Clin Exp Immunol. 96: 500-7. PMID: 8004820
7. Beneficial effect of polyclonal immunoglobulins from malaria-infected BALB/c mice on the lupus-like syndrome of (NZB x NZW)F1 mice.  |  Hentati, B., et al. 1994. Eur J Immunol. 24: 8-15. PMID: 8020574
8. Oligoclonality of T cells in salivary glands of autoimmune MRL/lpr mice.  |  Skarstein, K., et al. 1994. Immunology. 81: 497-501. PMID: 8039804
9. T cell receptor V beta gene expression in experimental herpes stromal keratitis.  |  Pedroza-Seres, M., et al. 1995. Eye (Lond). 9 (Pt 5): 599-604. PMID: 8543080
10. Characterization of T cell receptor repertoire and anti-Ro/SSA autoantibodies in relation to sialadenitis of NOD mice.  |  Skarstein, K., et al. 1995. Autoimmunity. 22: 9-16. PMID: 8882417

The preferred TCR β antibody is TCR β Antibody (G-11): sc-5277.